SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
The Company’s most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key […]
MarketWise – Annual Report and Shareholder Letter
BALTIMORE, March 07, 2024 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or “the Company”), a leading multi-brand digital subscription […]
Lilium Supports NYC EDC’s Decision to Seek Agnostic Operator for Downtown Manhattan Heliport & AAM’s Inclusion; Heliport will Serve as Key Site in Northeast Corridor Regional Network for Lilium Jet
Lilium celebrates NYC’s inclusion of all advanced air mobility capabilities and commitment to have an agnostic operator run the heliport […]
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, […]
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases […]
FuelCell Energy Reports First Quarter of Fiscal 2024 Results
First Quarter Fiscal 2024 Financial Summary(All comparisons are year-over-year unless otherwise noted) Revenues of $16.7 million compared to $37.1 million […]
Vital Farms Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Record Fourth Quarter Net Revenue of $135.8 million, up 23.4% versus Prior Year PeriodProvides Fiscal Year 2024 Outlook AUSTIN, Texas, […]
Altisource Announces Fourth Quarter and Full Year 2023 Financial Results
LUXEMBOURG, March 07, 2024 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider […]
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company’s sNDA. If approved, the Company is prepared for launch […]
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of […]
